Clinical Trial Update: Two-fraction HDR Monotherapy for Localized Prostate Cancer [NA]

View source ↗

Summary

A UCSF-led clinical trial is testing two-fraction high-dose-rate brachytherapy monotherapy for localized prostate cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: University of California, San Francisco | Conditions: Prostate Adenocarcinoma, Localized Prostate Carcinoma | NA | Status: RECRUITING